−0.38PLN
−39.28 MPLN
162.62 MPLN
21.03 M
About CLNPHARMA
Sector
CEO
Maciej Wieczorek
Headquarters
Lomianki
Website
Employees (FY)
523
Founded
2002
ISIN
PLCLNPH00015
FIGI
BBG00DSJ1T59
Celon Pharma SA is a pharmaceutical company, which engages in the research and manufacture of modern drugs. The firm's products include Aromek, Donepex, Ketrel, Salmex, and Valzek. It operates through the Generic Drug and Innovative segments. The Generic Drug segment pertains to the manufacture and sale of drugs registered and authorized for marketing. The Innovative segment involves activities that develop the documentation on the basis of which a drug could be registered or commercialized at the stage prior to drug registration. The company was founded by Maciej Wieczorek on June 20, 2002 and is headquartered in Lomianki, Poland.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of CLN is 14.78 PLN — it has decreased by 1.47% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on GPW exchange CLNPHARMA stocks are traded under the ticker CLN.
CLN stock is 1.63% volatile and has beta coefficient of 0.38. Check out the list of the most volatile stocks — is CLNPHARMA there?
One year price forecast for CLNPHARMA has a max estimate of 23.00 PLN and a min estimate of 12.00 PLN.
CLNPHARMA revenue for the last quarter amounts to 48.80 M PLN despite the estimated figure of 52.15 M PLN. In the next quarter revenue is expected to reach 54.10 M PLN.
Yes, you can track CLNPHARMA financials in yearly and quarterly reports right on TradingView.
CLN stock has fallen by 1.34% compared to the previous week, the month change is a 1.73% fall, over the last year CLNPHARMA has showed a 6.33% increase.
CLN net income for the last quarter is −6.82 M PLN, while the quarter before that showed 9.14 M PLN of net income which accounts for −174.54% change. Track more CLNPHARMA financial stats to get the full picture.
Yes, CLN dividends are paid annually. The last dividend per share was 0.09 PLN. As of today, Dividend Yield (TTM)% is 0.60%. Tracking CLNPHARMA dividends might help you take more informed decisions.
Like other stocks, CLN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CLNPHARMA stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 523.00 employees. See our rating of the largest employees — is CLNPHARMA on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CLNPHARMA technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CLNPHARMA stock shows the sell signal. See more of CLNPHARMA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on CLNPHARMA future price: according to them, CLN price has a max estimate of 23.00 PLN and a min estimate of 12.00 PLN. Read a more detailed CLNPHARMA forecast: see what analysts think of CLNPHARMA and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CLNPHARMA EBITDA is −19.87 M PLN, and current EBITDA margin is −15.78%. See more stats in CLNPHARMA financial statements.